These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

36 related articles for article (PubMed ID: 6831624)

  • 1. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
    Plosker GL; Faulds D
    Drugs; 1993 May; 45(5):788-856. PubMed ID: 7686469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tentative dose-monitoring of doxorubicin in lymphoma patients.
    Robert J; Vrignaud P; Eghbali H; Nguyen-Ngoc T; Hoerni B
    Med Oncol Tumor Pharmacother; 1985; 2(4):255-9. PubMed ID: 4087954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human pharmacokinetics of marcellomycin.
    Dodion P; Rozencweig M; Nicaise C; Watthieu M; Tamburini JM; Riggs CE; Bachur NR
    Cancer Chemother Pharmacol; 1985; 14(1):42-8. PubMed ID: 3965159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum and tissue concentrations of doxorubicin after IV administration of doxorubicin or doxorubicin-DNA complex to patients with gastrointestinal cancer.
    Gunvén P; Theve NO; Peterson C
    Cancer Chemother Pharmacol; 1986; 17(2):153-6. PubMed ID: 3719895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin.
    Smith DB; Margison JM; Lucas SB; Wilkinson PM; Howell A
    Cancer Chemother Pharmacol; 1987; 19(2):138-42. PubMed ID: 3471367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of doxorubicin in man: dose and schedule dependence.
    Erttmann R; Erb N; Steinhoff A; Landbeck G
    J Cancer Res Clin Oncol; 1988; 114(5):509-13. PubMed ID: 3182911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronopharmacokinetics of doxorubicin in patients with breast cancer.
    Canal P; Sqall A; de Forni M; Chevreau C; Pujol A; Bugat R; Roche H; Oustrin J; Houin G
    Eur J Clin Pharmacol; 1991; 40(3):287-91. PubMed ID: 2060566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of epirubicin and metabolites with repeated courses to cancer patients.
    Morris RG; Kotasek D; Paltridge G
    Eur J Clin Pharmacol; 1991; 40(5):481-7. PubMed ID: 1884722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative pharmacokinetics of doxorubicin given by three different schedules with equal dose intensity in patients with breast cancer.
    Twelves CJ; Dobbs NA; Aldhous M; Harper PG; Rubens RD; Richards MA
    Cancer Chemother Pharmacol; 1991; 28(4):302-7. PubMed ID: 1879047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.
    Twelves CJ; Dobbs NA; Michael Y; Summers LA; Gregory W; Harper PG; Rubens RD; Richards MA
    Br J Cancer; 1992 Oct; 66(4):765-9. PubMed ID: 1419619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of doxorubicin in sarcoma patients.
    Robert J; Bui NB; Vrignaud P
    Eur J Clin Pharmacol; 1987; 31(6):695-9. PubMed ID: 3556376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients.
    Vrignaud P; Eghbali H; Hoerni B; Iliadis A; Robert J
    Eur J Cancer Clin Oncol; 1985 Nov; 21(11):1307-13. PubMed ID: 3865777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J
    Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent pharmacokinetics and cancer chemotherapy.
    Powis G; Ames MM; Kovach JS
    Cancer Chemother Pharmacol; 1981; 6(1):1-9. PubMed ID: 7023712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early-phase pharmacokinetics of doxorubicin in non-Hodgkin lymphoma patients. Dose-dependent and time-dependent pharmacokinetic parameters.
    Robert J; Hoerni B; Vrignaud P; Lagarde C
    Cancer Chemother Pharmacol; 1983; 10(2):115-9. PubMed ID: 6831624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas].
    Robert J; Vrignaud P; Iliadis A; Eghbali H; Hoerni B
    Nouv Rev Fr Hematol (1978); 1983; 25(2):91-5. PubMed ID: 6866757
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.